Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06189495
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-11-13
Brief Title:
A Randomized Double-blind Placebo-controlled Phase II Clinical Study to Evaluate the Safety Tolerability Efficacy and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Sponsor:
Changchun GeneScience Pharmaceutical Co Ltd
Organization:
Changchun GeneScience Pharmaceutical Co Ltd
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Systemic Sclerosis Associated Interstitial Lung Disease |
| Rheumatoid Arthritis Associated Interstitial Lung Disease RA-ILD |
| Systemic Sclerosis Associated Interstitial Lung Disease SSc-ILD |